BeOne Medicines Ltd. - American Depositary Shares (ONC)
ONC moved a median of +0.22% 30 minutes after news, and +0.14% by the close. How ONC actually reacts to news — the realized, point-in-time move the market made, measured across 204 labeled events over the last three years with zero look-ahead.
ONC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.20% | 57% | 202 |
| 30-min | +0.22% | 55% | 202 |
| 60-min | +0.06% | 51% | 202 |
| to close | +0.14% | 52% | 201 |
| Middle 50% of ONC reactions | -0.43% to +0.85% |
|---|---|
| Median reaction (30-min) | +0.22% |
| Measured reactions | 204 |
Half of all BeOne Medicines Ltd. - American Depositary Shares news events land between -0.43% and +0.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ONC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.56% | 40% | -0.20% |
| Coverage initiations | 14 | +0.61% | 86% | -0.20% |
| Rating reiterations | 69 | -0.04% | 46% | -0.14% |
| Price-target raises | 25 | +0.03% | 52% | +0.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ONC ranks against every other measured name →
That’s how ONC usually reacts — get an email when it moves on news →Email me when ONC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ONC's baseline. Nothing else.
Recent ONC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference | Press release | Business Wire | +1.44% | +1.97% | |
| BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer | Press release | Business Wire | -0.48% | +0.86% | |
| BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | Press release | Business Wire | -0.05% | +0.40% | |
| BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA | Press release | Business Wire | -0.14% | +0.14% | |
| BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries | Press release | Business Wire | +0.35% | +1.42% | |
| BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration | Press release | Business Wire | — | — | |
| BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates | Press release | Business Wire | +0.22% | -0.45% | |
| BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines | Press release | Business Wire | +0.02% | +1.99% | |
| BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5 | Press release | Business Wire | -0.65% | +1.44% | |
| BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma | Press release | Business Wire | -0.41% | -0.09% | |
| BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026 | Press release | Business Wire | +1.28% | +1.08% | |
| BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit | Press release | Business Wire | +0.53% | +1.60% | |
| BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 | Press release | Business Wire | -0.88% | -2.04% | |
| BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 | Press release | Business Wire | -0.41% | -1.83% | |
| BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 | Press release | Business Wire | -1.26% | -1.48% | |
| BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +0.10% | -2.76% | |
| BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | Press release | Business Wire | -0.81% | +1.29% | |
| BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard | Press release | Business Wire | +1.29% | +2.35% | |
| BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma | Press release | Business Wire | +0.99% | +0.33% | |
| BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates | Press release | Business Wire | -1.69% | +2.23% | |
| U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA | Press release | Business Wire | -0.33% | -1.63% | |
| BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6 | Press release | Business Wire | +0.55% | -0.14% | |
| BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership | Press release | Business Wire | -0.43% | -1.90% | |
| BeOne Medicines to Present at Upcoming Investor Conferences | Press release | Business Wire | +0.36% | +2.54% | |
| BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 | Press release | Business Wire | -1.82% | -0.62% | |
| BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.40% | +3.51% | |
| ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA | Press release | Business Wire | +0.02% | +0.14% | |
| BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -1.32% | -0.06% | |
| BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma | Press release | Business Wire | +1.05% | +0.40% | |
| BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia | Press release | Business Wire | +0.87% | +0.46% | |
| Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies | Press release | Business Wire | +0.87% | +0.46% | |
| U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Press release | Business Wire | +0.37% | -0.96% | |
| BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 | Press release | Business Wire | -0.34% | -3.47% | |
| Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma | Press release | Business Wire | -0.24% | -0.36% | |
| BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates | Press release | Business Wire | -0.25% | +3.75% | |
| BeOne Medicines to Present at Upcoming Investor Conferences | Press release | Business Wire | +0.64% | +0.93% | |
| BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 | Press release | Business Wire | +0.00% | +0.99% | |
| The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners | Press release | PR Newswire | +0.05% | -0.41% | |
| BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 | Press release | Business Wire | +0.02% | +0.19% | |
| BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA | Press release | Business Wire | +0.20% | +1.39% | |
| BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Press release | Business Wire | +0.09% | -1.50% | |
| European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 | Press release | Business Wire | -0.78% | +0.40% | |
| BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | Business Wire | -0.60% | +0.02% | |
| BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million | Press release | Business Wire | -0.46% | -3.37% | |
| European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications | Press release | Business Wire | +0.01% | +1.23% | |
| BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates | Press release | Business Wire | -1.47% | -4.38% | |
| BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia | Press release | Business Wire | +0.21% | +1.56% | |
| BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment | Press release | Business Wire | -0.67% | -1.50% | |
| BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 | Press release | Business Wire | +1.83% | +2.26% | |
| European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma | Press release | Business Wire | -0.26% | -0.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ONC section they belong to.
Where else ONC is measured.
ONC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BeOne Medicines Ltd. - American Depositary Shares's median reaction calculated?
Every labeled ONC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 204 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of ONC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ONC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.